GH Research (GHRS) Interest & Investment Income (2022 - 2026)
GH Research (GHRS) posted quarterly Interest & Investment Income of $2.5 million for Q4 2025, up 18.88% year-over-year from $2.1 million in Q4 2024, and down 9.74% quarter-over-quarter from $2.8 million in Q3 2025.
Analysis
GH Research (GHRS) Interest & Investment Income (2022 - 2026) Analysis & Trends
GH Research's Interest & Investment Income history runs 4 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- In Q4 2025, Interest & Investment Income rose 18.88% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $11.1 million (up 12.71% YoY), while the FY2025 annual figure was $11.1 million, up 12.71% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $2.5 million, down from $2.8 million in the prior quarter.
- The five-year high for Interest & Investment Income was $3.1 million in Q2 2025, with the low at $1.2 million in Q4 2022.
- The 4-year median for Interest & Investment Income is $2.5 million (2024), against an average of $2.4 million.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 151.2% in 2023, then decreased 27.86% in 2024.
- GH Research's Interest & Investment Income stood at $1.2 million in 2022, then surged by 151.2% to $2.9 million in 2023, then decreased by 27.86% to $2.1 million in 2024, then grew by 18.88% to $2.5 million in 2025.
- Business Quant data shows GHRS's Interest & Investment Income at $2.5 million in Q4 2025, $2.8 million in Q3 2025, and $3.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | GH Research | 1.70 Bn | 1.33 Bn | - | 2.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.66 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 2.76 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 2.93 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.12 Mn |
| Mar 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.17 Mn |